Table 2.
Comparison of clinical features and examinations before and during COVID-19 pandemic
| 2018 | 2019 | 2020 | 2018 vs 2020 | 2019 vs 2020 | |
|---|---|---|---|---|---|
| (n = 104) | (n = 101) | (n = 67) | p | p | |
| Initial symptom, (%) | 0.010 | 0.131 | |||
| Regular physical examination | 18(17.3) | 11(10.9) | 2(3.0) | ||
| Mild | 61(58.7) | 66(65.3) | 51(76.1) | ||
| Severe | 25(24.0) | 24(23.8) | 14(20.9) | ||
| Median days from symptom to medical visit (P25, P75) | 90.00 (50.00, 180.00) | 90.00 (30.00, 150.00) | 90.00 (30.00, 165.00) | 0.290 | 0.857 |
| Median day from diagnosis to admission (P25, P75) | 7.00 (4.00, 12.00) | 8.00 (5.00, 14.00) | 13.50 (8.00,27.00) | < 0.001 | < 0.001 |
| Tumor circumference of the lumen, (%) | 0.090 | 0.327 | |||
| 1/4 | 22(21.2) | 14(13.9) | 6(9.1) | ||
| 1/2 | 26(25.0) | 23(22.8) | 13(19.7) | ||
| 3/4 | 17(16.3) | 32(31.7) | 17(25.8) | ||
| Total | 39(37.5) | 32(31.7) | 30(45.5) | ||
| Ileus, (%) | 1.000 | 1.000 | |||
| No | 97(93.3) | 94(93.1) | 63(94.0) | ||
| Incomplete or complete ileus | 7(6.7) | 7(6.9) | 4(6.0) | ||
| Hb, g/L, ±s | 121.2 ± 26 | 119.1 ± 25.23 | 121.0 ± 23.1 | 0.956 | 0.620 |
| Alb, g/L, ±s | 39.0 ± 5.1 | 38.7 ± 3.5 | 38.5 ± 3.7 | 0.462 | 0.670 |
| CEA, ng/mL, ±s | 12.0 ± 18.1 | 24. ± 143.0 | 40.8 ± 72.0 | 0.390 | 0.659 |
| CA19-9, U/L, ±s | 18.5 ± 45.3 | 18.3 ± 41.3 | 196.8 ± 1464.4 | 0.323 | 0.322 |
| Tumor location, (%) | 0.335 | 0.090* | |||
| Ileocecal junction | 5(4.8) | 0 | 1(1.5) | ||
| Ascending colon | 11(10.6) | 23(22.8) | 9(13.4) | ||
| Hepatic flexure of colon | 9(8.7) | 0 | 1(1.5) | ||
| Transverse colon | 2(1.9) | 0 | 1(1.5) | ||
| Splenic flexure of colon | 2(1.9) | 0 | 3(4.5) | ||
| Descending colon | 5(4.8) | 6(5.9) | 3(4.5) | ||
| Sigmoid colon | 28(26.9) | 24(23.8) | 14(20.9) | ||
| Rectum | 42(40.4) | 48(47.5) | 35(52.2) |